 RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2020 GLOBE NEWSWIRE -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that Rosty Raykov, Chief Executive Officer of Fennec will present at the following upcoming investor conferences. The following presentations will be webcast live and can be accessed by visiting the investors relations section of the Companys website at A replay of each presentation will also be available and archived on the site for 90 days. 2020 Wedbush PacGrow Healthcare Conference Presentation being held on Wednesday, August 12, at 2:55 p.m. ET. H.C. Wainwright Global Investment Conference Presentation being held on September 14-16. Cantor Fitzgerald Virtual Global Healthcare Conference Presentation being held on September 15th, at 12:20 pm ET.About PEDMARKTM A unique formulation of sodium thiosulfate STSCisplatin and other platinum compounds are essential chemotherapeutic agents for many pediatric malignancies. Unfortunately, platinum-based therapies cause ototoxicity, or hearing loss, which is permanent, irreversible and is particularly harmful to the survivors of pediatric cancer.In the U.S. and Europe, it is estimated annually that over 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this type of hearing loss and only expensive, technically difficult and sub-optimal cochlear inner ear implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.PEDMARK has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Children Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.The Marketing Authorization Application MAA for sodium thiosulfate tradename PEDMARQSI is currently under evaluation by the European Medicines Agency EMA. PEDMARK has received Breakthrough Therapy and Fast Track Designation by the FDA in March 2018.About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this setting. Fennec has a license agreement with Oregon Health and Science University OHSU for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit Statements Except for historical information described in this press release, all other statements are forward-looking. These forward-looking statements include the Companys expectations regarding its interactions and communications with the FDA, including its expectation to discuss with the FDA the issues raised in the CRL and the Companys plans to address them. Forward-looking statements are subject to certain risks and uncertainties inherent in the Companys business that could cause actual results to vary, including such risks and uncertainties that regulatory and guideline developments may change, scientific data andor manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, Fennecs reliance on third party manufacturing, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus COVID-19, or surrounding the duration and severity of an outbreak, protection offered by the Companys patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Companys products will not be as large as expected, the Companys products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Companys filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Fennec disclaims any obligation to update these forward-looking statements except as required by law.For a more detailed discussion of related risk factors, please refer to our public filings available at and further information, please contact:Investors: Rosty Raykov Chief Executive Officer Fennec Pharmaceuticals Inc. 1 919-636-5144 